Melanie Aitken

Melanie Aitken is the Managing Principal of Bennett Jones (US) LLP. She is also co-head of the competition and foreign investment practice of Bennett Jones. She specializes in global antitrust and competition law and litigation.

Melanie served as Canada’s Competition Commissioner, in charge of the Canadian Competition Bureau from 2009 to 2012, having previously served as the Senior Deputy Commissioner leading merger review from 2006 to 2009.

While serving as Commissioner, Melanie led many high-profile civil and criminal matters and worked extensively with leaders of international antitrust authorities around the world on enforcement and policy cases, holding leadership roles in key international organizations, such as the Steering Committee of the International Competition Network.

Melanie was a partner at Bennett Jones and Davies Ward Philips & Vineberg before joining the Bureau in 2005. She has acted as counsel in the Supreme Court of Canada and represented the merging parties in Canada’s leading efficiencies case, Superior Propane. Melanie has an active antitrust advisory, trial and commercial practice, representing major Canadian and US companies in significant matters across a broad range of industries.

Melanie is a frequent speaker and commentator on competition issues, and has taught as an Adjunct Professor at Osgoode Hall and Queen’s Law Schools. She is active on the C.D. Howe Institute’s Competition Policy Council, and sits on the Advisory Boards of the Global Antitrust Institute, Schulich School of Business (Toronto, Canada), and W@CompetitionAmericas, and has been appointed a Fellow of the American Bar Foundation. Melanie also serves as a non-governmental advisor to the International Competition Network.

The United States Cannot Afford Disarray as China Strengthens Its Biopharmaceutical Industry

By Sujai Shivakumar, Charles Wessner, and Julie Heng For years, China has played a leading role in manufacturing active pharmaceutical ingredients and generic drugs. While securing the supply chain for active pharmaceutical ingredients is increasingly recognized as a national security priority by policymakers, China’s growing role in biotechnological innovation has
Read More

Explainer: A Brief History of the International IP Regime

By Julie Heng, Arrizka Faida, and Chris Borges In a globalized economy, businesses rely on rules protecting intellectual property (IP) to safeguard their ideas and products against counterfeiting, piracy, and theft and to forge international partnerships. To this end, the United States and its partners have long invested in a system of multilateral treaties and international
Read More

ChinaTalk: Innovation Emergency with Trump 1.0’s Patent Director

On February 19th, CSIS Senior Adviser Andrei Iancu appeared on the ChinaTalk podcast to discuss how patents influence emerging technology innovation, how far AI and DOGE could push the current U.S. IP regime, if it matters that China issues more patents than the United States, and more. Listen to the
Read More